Q2 2024 Earnings Forecast for Mustang Bio, Inc. Issued By HC Wainwright (NASDAQ:MBIO)

Mustang Bio, Inc. (NASDAQ:MBIOFree Report) – Investment analysts at HC Wainwright issued their Q2 2024 earnings per share estimates for Mustang Bio in a research report issued to clients and investors on Monday, May 13th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings of ($0.13) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $2.00 price objective on the stock. The consensus estimate for Mustang Bio’s current full-year earnings is ($3.25) per share. HC Wainwright also issued estimates for Mustang Bio’s Q3 2024 earnings at ($0.16) EPS, Q4 2024 earnings at ($0.15) EPS and FY2025 earnings at ($0.38) EPS.

Mustang Bio Stock Performance

Shares of NASDAQ MBIO opened at $0.26 on Tuesday. The business has a 50-day simple moving average of $0.70 and a two-hundred day simple moving average of $1.17. Mustang Bio has a 52 week low of $0.22 and a 52 week high of $8.17.

Mustang Bio (NASDAQ:MBIOGet Free Report) last released its quarterly earnings data on Monday, March 11th. The company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.68) by $0.97.

Hedge Funds Weigh In On Mustang Bio

A hedge fund recently bought a new stake in Mustang Bio stock. Armistice Capital LLC purchased a new position in Mustang Bio, Inc. (NASDAQ:MBIOFree Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 435,764 shares of the company’s stock, valued at approximately $588,000. Armistice Capital LLC owned 4.73% of Mustang Bio as of its most recent filing with the Securities and Exchange Commission (SEC). 9.95% of the stock is currently owned by hedge funds and other institutional investors.

Mustang Bio Company Profile

(Get Free Report)

Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Featured Stories

Earnings History and Estimates for Mustang Bio (NASDAQ:MBIO)

Receive News & Ratings for Mustang Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mustang Bio and related companies with MarketBeat.com's FREE daily email newsletter.